6 Место заместительной почечной терапии в ИТ сепсиса
.pdf
Programme
Moderator:
Professor Mikael Bodelsson, Dept of Anaesthesiology
Lund University, Sweden
16.00Welcome
Jonas Jönmark, President Alteco Medical AB
16.10Clinical Experiences from LPS Adsorption Sepsis/Septic Shock
MD, PhD Elena Gromova, Head Dept. of Intensive Russian Cancer Research Centre, Moscow,
16.40LPS Adsorber in Septic Shock: Observational
Professor Tero Ala-Kokko, Head of Intensive Oulu University Hospital, Finland
17.10Clinical Efficacy of Adsorption of LPS in the Severe Sepsis
MD, PhD, Vladimir Kulabukhov, Head of Dept. Purulent-Septic Surgery Clinic, Moscow, Russia
17.40Discussion & Summary
18.00Cocktail Buffet
Russian |
National |
Medical |
|
|
|
|
|
|
|
|
|
||||||
|
|
Surgical |
|
|
|
|
|
|
|||||||||
|
|
|
|
|
Center |
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
by |
|
|
Department |
|
|
|
|
|
|
|
|
|
|
|
|
I |
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
.M |
|||||
|
|
|
|
ofAnesthesiology |
|
|
|
|
|
. Pirogov |
|||||||
|
|
Purulent |
|
|
|
|
and |
|
|
|
|
||||||
|
|
|
|
|
|
-Septic |
|
|
|
Intensive |
Care, |
||||||
|
|
|
|
|
|
|
|
|
Surgery |
Clinic |
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
ofAdsorption |
Clinical |
Efficacy |
|
|
|
|
|
|
|
||||||||
of LPS |
|
|
|
|
|
|
|
|
|
||||||||
in the Treatment |
|
|
|
||||||||||||||
|
of Gram |
||||||||||||||||
Negative |
|
||||||||||||||||
Severe Sepsis |
|
|
|||||||||||||||
|
|
|
|
|
|
|
|
||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Vl |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
!dimir |
Kulabukhov |
|||||||
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Symposium: |
|
|
|
October |
11 |
|
|
|
|
|
|
|
|
|||
|
|
|
«Alteco® |
LPS |
-th, 2010 |
|
|
|
|
|
|
||||||
|
|
|
|
with life |
Adsorber |
treatment |
|
|
|
|
|||||||
|
|
|
|
threatening |
|
for patients |
|||||||||||
|
|
|
|
|
|
|
|
sepsis» |
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
Эффективность Alteco LPS сорбции в комплексной терапии сепсиса
47
четверг, 26 мая 2011 г.
|
LPS adsorber treatment |
|
|
|
Aquarius (Edwards Life Science, US |
||
|
Blood flow 150±50 ml/min |
|
|
|
Treatment time120 min |
|
|
|
Two treatments with an interval of 24 hours |
||
0 |
24 h |
48 h |
72 h |
|
treatment |
|
|
четверг, 26 мая 2011 г. |
|
|
|
|
LPS adsorber treatment |
|
|
|
Aquarius (Edwards Life Science, US |
||
|
Blood flow 150±50 ml/min |
|
|
|
Treatment time120 min |
|
|
|
Two treatments with an interval of 24 hours |
||
1 |
|
|
|
0 |
24 h |
48 h |
72 h |
|
treatment |
|
|
четверг, 26 мая 2011 г. |
|
|
|
|
LPS adsorber treatment |
|
|
|
Aquarius (Edwards Life Science, US |
||
|
Blood flow 150±50 ml/min |
|
|
|
Treatment time120 min |
|
|
|
Two treatments with an interval of 24 hours |
||
1 |
2 |
|
|
0 |
24 h |
48 h |
72 h |
|
treatment |
|
|
четверг, 26 мая 2011 г. |
|
|
|
|
|
LPS adsorber treatment |
|
|
|
|
Aquarius (Edwards Life Science, US |
||
|
|
Blood flow 150±50 ml/min |
|
|
|
|
Treatment time120 min |
|
|
|
|
Two treatments with an interval of 24 hours |
||
1 |
2 |
3 |
|
|
|
0 |
24 h |
48 h |
72 h |
|
treatment |
|
|
|
четверг, 26 мая 2011 г. |
|
|
|
|
|
|
LPS adsorber treatment |
|
|
|
|
Aquarius (Edwards Life Science, US |
||
|
|
Blood flow 150±50 ml/min |
|
|
|
|
Treatment time120 min |
|
|
|
|
Two treatments with an interval of 24 hours |
||
1 |
2 |
3 |
4 |
|
|
0 |
24 h |
48 h |
72 h |
|
treatment |
|
|
|
четверг, 26 мая 2011 г. |
|
|
|
|
|
|
|
LPS adsorber treatment |
|
|
|
|
Aquarius (Edwards Life Science, US |
|||
|
|
|
Blood flow 150±50 ml/min |
|
|
|
|
|
Treatment time120 min |
|
|
|
|
Two treatments with an interval of 24 hours |
|||
1 |
2 |
3 |
4 |
5 |
|
|
0 |
24 h |
48 h |
72 h |
|
|
treatment |
|
|
|
|
четверг, 26 мая 2011 г. |
|
|
|
|
|
|
|
|
LPS adsorber treatment |
|
|
|
|
Aquarius (Edwards Life Science, US |
|||
|
|
|
Blood flow 150±50 ml/min |
|
|
|
|
|
Treatment time120 min |
|
|
|
|
Two treatments with an interval of 24 hours |
|||
1 |
2 |
3 |
4 |
5 |
6 |
|
0 |
24 h |
48 h |
72 h |
|
|
treatment |
|
|
|
|
четверг, 26 мая 2011 г. |
|
|
|
|
|
Dynamics of the level of Endotoxin (LPS)
(EU/ml)
LPS |
Control 1,5 |
1,125
0,75
0,375
1,44 1,44 |
0,57 1,44 |
0,72 |
1,44 |
|
|
|
|
|
|
1 |
2 |
0,36 |
1,44 |
|
|
|
|
||
|
3 |
|
0,36 |
0,82 |
|
0 |
|||
|
|
|
4 |
|
0,1 |
||||
|
|
|
|
|
|
5 |
0,82 |
||
|
|
|
|
|
|
|
|
|
6 |
четверг, 26 мая 2011 г.
Dynamics of the level of Procalcitonin, PCT (ng/ml)
20
LPS Control
15
10
5
16 |
15,6 |
10 |
16,1 |
11,6 16,4 |
|
|
|
|
|
|
|
1 |
|
2 |
7,5 |
15,9 |
|
|
|
|
|
|
|
|
3 |
4,2 |
14,3 |
1,4 |
0 |
|||
|
|
|
|
|
|
4 |
|
5 |
13,6 |
|
|
|
|
|
|
|
|
|
|
|
6 |
четверг, 26 мая 2011 г.